Kite Pharma

Last updated
Kite Pharma, Inc.
Company type Subsidiary
Industry Biopharmaceutical
Founded2009;15 years ago (2009)
Founder Arie Belldegrun and Joshua Kazam
FateAcquired by Gilead Sciences
Headquarters
Santa Monica
,
California
Key people
  • Christi Shaw (CEO)
  • Mert Aktar (Head of Corporate Development)
  • Warner Biddle (Global Head of Commercial)
[1]
Products Cancer immunotherapy
Number of employees
2,000
Parent Gilead Sciences
Website www.kitepharma.com
Footnotes /references
Key People, [2] [3] Founder [3] [1]

Kite Pharma is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.

Contents

History

The company was founded in 2009 by Arie Belldegrun, an Israeli-American oncologist, who served as the company's chairman, president and chief executive officer. [2] [4] Belldegrun had a co-founder in Joshua Kazam, who took on the role of Director. [3]

On August 28, 2017, Gilead Sciences announced that it would acquire Kite Pharma for $11.9 billion in an all-cash deal, a 29% premium on the share price. [5] Gilead made the purchase in large part to bolster sales in the face of the company's declining hepatitis C franchise revenues, a result of declining patient numbers as they were cured, as Kite's sales were anticipated to reach $2 billion per annum. [6] The acquisition was completed in October 2017, [7] when Kite Pharma's Yescarta became the first CAR-T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. [8] This form of immunotherapy was originally developed by the U.S. National Cancer Institute and the company pays the government to support continuing research. [9]

In 2017, MIT Technology Review ranked Kite Pharma 7th in its annual list of the preceding year's 50 Smartest Companies. [10]

Lead product

Axicabtagene ciloleucel (KTE-C19, ZUMA-3, YESCARTA) was an investigational therapy (for the treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL)) in which a patient's T cells were genetically modified to express a chimeric antigen receptor designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias. [11] It garnered a US FDA Breakthrough Therapy Designation (Dec 2015) for the treatment of patients with refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), and transformed follicular lymphoma (TFL). [12] It was approved for use in the United States under the brand name YESCARTA in October 2017. [3]

Development history

2012

In October, Kite Pharma entered into a Cooperative Research and Development Agreement with the National Cancer Institute (NCI) for the development and commercialization of products for the treatment of multiple cancer indications. [13]

2013

In December, the company announced data in its lead clinical development program with the NCI, demonstrating that Kite's most advanced immunotherapy product candidate – KTE-C19 CAR – can produce robust and durable tumor shrinkage in patients with an aggressive form of non-Hodgkin's lymphoma, known as diffuse large B cell lymphoma (DLBCL). [14] The clinical data were presented at the 55th American Society of Hematology Annual Meeting. [15]

2014

The company announced in March, that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation for the company's proposed therapy for DLBCL. [16]

In June, Kite Pharma entered into an exclusive, worldwide license with the National Institutes of Health (NIH) to certain intellectual property related to TCR-based product candidates that target the NY-ESO-1 antigen for the treatment of cancers expressing NY-ESO-1. [17]

Kite Pharma announced findings from its ongoing clinical trial in August: 12 of 13 evaluable patients with advanced B-cell malignancies had complete remissions (8 patients) or partial remissions (4 patients) resulting in a 92% objective response rate. The results support Kite Pharma's plan to file an Investigational New Drug (IND) application in the fourth quarter of 2014 to initiate a clinical trial of Kite Pharma's lead CAR-based product candidate, KTE-C19, in patients with DLBCL. [18]

2015

In January, Kite Pharma and Amgen entered into a strategic research collaboration and license agreement to develop and commercialize the next generation of novel Chimeric Antigen Receptor (CAR) T cell immunotherapies based on Kite's engineered autologous cell therapy platform and Amgen's extensive array of cancer targets. [19] [20]

Kite Pharma announced in May, that the first patient in its Phase 1/2 clinical trial of KTE-C19 in patients with refractory aggressive Non-Hodgkin's Lymphoma has been treated. [21]

In June, Kite Pharma and bluebird bio, Inc. announced they have entered into a collaboration agreement to co-develop and co-commercialize second generation T cell receptor product candidates directed against the human papillomavirus type 16 E6 onco protein incorporating gene editing and lentiviral technologies. [22]

In July, Kite Pharma and the Leukemia & Lymphoma Society announced that they have entered into a partnership to enhance the development of Kite's lead product candidate, KTE-C19, for the treatment of patients with refractory aggressive Non-Hodgkin's Lymphoma. [23]

In September, Kite Pharma announced that it has expanded its collaboration with the Netherlands Cancer Institute (NKI). Kite and the NKI have entered into an agreement under which Kite will receive from the NKI the exclusive option to license multiple T cell receptor (TCR) gene sequences for the development and commercialization of cancer immunotherapy candidates targeting solid tumors. Kite has also expanded its access to additional resources and research facilities through a master services agreement with the NKI. [24]

In October, Kite Pharma announced that it has entered into an exclusive, worldwide license with the National Institutes of Health (NIH) for intellectual property related to T cell receptor (TCR)-based product candidates directed against MAGE A3 and A3/A6 antigens for the treatment of tumors expressing MAGE, which include lung, pancreatic, gastric, and breast cancers, among others. [25] In the same month, Kite Pharma announced that it has entered into a worldwide research and license agreement with Alpine Immune Sciences (AIS), a privately held biotechnology startup, to discover and develop protein-based immunotherapies targeting the immune synapse to treat cancer. AIS will grant Kite an exclusive license to two programs from its Transmembrane immunomodulatory protein (TIP) technology, which Kite plans to further engineer into chimeric antigen receptor (CAR) and T cell receptor (TCR) product candidates. This collaboration will accelerate Kite's efforts to establish the next generation of engineered T cell therapies specifically designed to overcome the inhibitory mechanisms present in the tumor micro-environment. [26] [27]

In December, Kite Pharma announced that it has initiated a phase 1/2 clinical study of KTE-C19 (ZUMA-3) for the treatment of adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL). KTE-C19 is an investigational therapy in which a patient's T cells are genetically modified to express a chimeric antigen receptor designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemia's. [11] In the same month, Kite Pharma and GE Global Research announced they will partner to develop a next-generation, functionally integrated and automated manufacturing system for engineered T-cell therapy. Kite and GE Global Research—GE's centralized R&D hub—said they aim to increase the availability of engineered T-cell therapies by speeding up development of automation technologies that have the potential to lower costs, operate faster, and minimize variability. [28] Also in December, Kite announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation status to the company's lead product candidate, KTE-C19, for the treatment of patients with refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), and transformed follicular lymphoma (TFL). [12]

2016

In January, it was announced that Kite Pharma has entered into a Cooperative Research and Development Agreement (CRADA) with the NCI for the research and clinical development of a fully human anti-CD19 chimeric antigen receptor (CAR) product candidate for the treatment of B-cell lymphomas and leukemia. [29] Moreover, Kite Pharma announced that its European subsidiary has entered into a research and license agreement with Leiden University Medical Center (LUMC) to identify and develop T cell receptor (TCR) product candidates targeting solid tumors that are associated with the human papillomavirus (HPV) type 16 infection. [30]

In March, Kite Pharma has announced that it would be collaborating with Genentech, in order to evaluate the safety and efficacy of two of its novel therapies. The target population for the tests would be patients with non-Hodgkin Lymphoma. The therapies in question, KTE-C19 and atezolizumab, would be tested in combination with each other. [31]

In June, Kite Pharma and Cell Design Labs, Inc. announced a research collaboration and license agreement to develop next generation, precision-controlled chimeric antigen receptor (CAR) product candidates that incorporate Cell Design Labs' molecular “on/off switch” technology. [32] Also in June, Kite Pharma announced that it has entered into a new Cooperative Research and Development Agreement (CRADA) with the Experimental Transplantation and Immunology Branch (ETIB) of the National Cancer Institute (NCI) for the research and clinical development of T-cell receptor (TCR) product candidates directed against human papillomavirus (HPV)-16 E6 and E7 onco-proteins for the treatment of HPV-associated cancers. [33]

In July, Kite Pharma announced that it has entered into an exclusive, worldwide license agreement with The Regents of the University of California, on behalf of the University of California, Los Angeles (UCLA), for technology to advance the development of off-the-shelf allogeneic T-cell therapies from renewable pluripotent stem cells. [34]

In December, Kite Pharma and Vitruvian Networks, Inc., a pioneering cell and gene therapy software and analytics platform company co-founded by GE Ventures and the Mayo Clinic, announced a strategic partnership to create a software solution to support commercial availability of T-cell therapies. Together, the parties will design and develop a platform for patients, physicians and treatment centers that enables commercial-scale ordering, logistics, monitoring and delivery of autologous cell therapies if they are FDA-approved, including axicabtagene ciloleucel (formerly known as KTE-C19), Kite's lead investigational engineered T-cell therapy for aggressive non-Hodgkin lymphoma. [35]

2017

In March, Kite announced results a clinical trial of CAR-T cells in around a hundred people with advanced Non-Hodgkin lymphoma. [36]

In April, Kite has won the ‘Clinical Trial Result of the Year’ award for its CAR-T trial of Axicabtagene Ciloleucel in patients with Aggressive Non-Hodgkin Lymphoma at the Clinical and Research Excellence Awards. The award recognizes clinical achievements in the pharmaceutical industry and contribution to the advancement of therapies for unmet medical needs. [37]

In August, Kite has filed the first CAR-T candidate in Europe, seeking approval of its axicabtagene ciloleucel (KTE-C19) for two types of non-Hodgkin's lymphoma (NHL). [38]

Business history

In March 2011, Kite Pharma received $15 million in Series A venture cash. [39]

In May 2013, Kite Pharma completed a $35 million financing of Series A preferred stock. [40] [41] [42]

In April 2014, Kite Pharma completed a $50 million mezzanine private financing of convertible notes. [43] [44]

In May 2014, Kite Pharma filed a registration with the SEC for an initial public offering (IPO) of its common stock. [45]

In June 2014, Kite Pharma sold 8,625,000 shares of its common stock in their IPO at $17.00 per share, for gross proceeds of $146.6 million. [46] [47] [48] The company listed on the NASDAQ Global market under the symbol “KITE.”

In December 2014, Kite Pharma sold 4,007,750 shares of it common stock in their follow-on offering at $54.00 per share, for gross proceeds of $216.4 million. [49]

In March 2015, Kite Pharma acquired T-Cell Factory (TCF), a privately held biotechnology company based in the Netherlands, for €20 million and renamed it – Kite Pharma EU. Per the deal, Kite Pharma has obtained license agreements with IBA GmbH, Sanquin Blood Supply Foundation and the Netherlands Cancer Institute (NKI), which include the rights to select new intellectual property related to T-cell receptors (TCRs) developed at the NKI. Additionally, the TCF acquisition will allow Kite Pharma to access the European manufacturing facilities, paving way for the company to initiate development programs in the EU and build its presence in the region. [50] [51]

In December 2015, Kite Pharma sold 4,168,750 shares of its common stock in a public offering at $69.00 per share, for gross proceeds of $287.6 million. [52]

In January 2017, Kite Pharma announced that it has partnered with Daiichi Sankyo Co Ltd to develop and commercialize its cancer treatment therapy in Japan, putting the U.S. company in line to receive up to $250 million in payments, of the $250 million, Kite said it would receive $50 million as upfront payment. [53] Also in January, Kite Pharma announced that it had formed a joint venture with Fosun Pharmaceutical to develop and commercialize its cancer treatment in China. Kite Pharma said it would receive an upfront payment of $40 million from the joint venture, funded by Fosun Pharma as well as regulatory and commercial milestones totaling $35 million. [54]

On August 28, 2017, Gilead Sciences announced that it would purchase Kite Pharma for US$11.9 billion in cash ($180.00 per share). [55] The purchase was subsequently completed for the announced price on October 3, 2017. [3] [56]

The company has primary leading manufacturing facilities in El Segundo, CA next to Los Angeles International airport and Amsterdam, Netherlands to support US, Canada, Australia and European markets. Kite is in the process of coordinating additional manufacturing capacity from its recent expansion into Urbana, Maryland facility as of 2023 as a strategic center that could accommodate same-day service to both California and Netherlands manufacturing operations. [57]

In February 2023, the business completed its acquisition of Tmunity Therapeutics [58]

Allogene Therapeutics

Following the sale of Kite to Gilead, Kite's founders and its CMO struck a deal in February 2018 with Pfizer to develop CAR-T therapeutics, leading to the creation of Allogene Therapeutics. The three former Kite executives subsequently hired into Allogene a number of people who left Kite after its sale. The notion behind Allogene was to create a 'next generation CAR-T' which was not tailored to a single individual, as YESCARTA was, but rather could be used in multiple patients, an allogeneic CAR-T. Pfizer received a 25% stake in Allogene and two seats on the company's board, while Allogene received rights to sixteen pre-clinical CAR-T assets and one Phase 1 allogeneic CAR-T clinical asset. Allogene's Series A funding was US$300 million, including Texas Pacific Group, University of California, Two River—and even Gilead as participants, among others. In October 2019, Allogene's initial public offering netted US$324 million and a capital valuation of US$3 billion. [3]

See also

Related Research Articles

A cancer vaccine, or oncovaccine, is a vaccine that either treats existing cancer or prevents development of cancer. Vaccines that treat existing cancer are known as therapeutic cancer vaccines or tumor antigen vaccines. Some of the vaccines are "autologous", being prepared from samples taken from the patient, and are specific to that patient.

In biology, chimeric antigen receptors (CARs)—also known as chimeric immunoreceptors, chimeric T cell receptors or artificial T cell receptors—are receptor proteins that have been engineered to give T cells the new ability to target a specific antigen. The receptors are chimeric in that they combine both antigen-binding and T cell activating functions into a single receptor.

<span class="mw-page-title-main">Cancer immunotherapy</span> Artificial stimulation of the immune system to treat cancer

Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight the disease. It is an application of the fundamental research of cancer immunology (immuno-oncology) and a growing subspecialty of oncology.

<span class="mw-page-title-main">B-cell maturation antigen</span> Protein-coding gene in the species Homo sapiens

B-cell maturation antigen, also known as tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a protein that in humans is encoded by the TNFRSF17 gene.

<span class="mw-page-title-main">Lutzner cells</span>

Lutzner cells were discovered by Marvin A. Lutzner, Lucien-Marie Pautrier, and Albert Sézary. These cells are described as the smaller forms of Sézary cells, or Sézary-Lutzner cells, and the two variants are recognised as being morphologically different. Aggregates of these cells in mycosis fungoides are known as a Pautrier's microabscesses. They are a form of T-lymphocytes that has been mutated This atypical form of T-lymphocytes contains T-cell receptors on the surface and is found in both the dermis and epidermis layers of the skin. Since Lutzner cells are a mutated form of T-lymphocytes, they develop in bone marrow and are transported to the thymus is order to mature. The production and maturation stages occur before the cell has developed a mutation. Lutzner cells can form cutaneous T-cell lymphoma, which is a form of skin cancer.

Adoptive cell transfer (ACT) is the transfer of cells into a patient. The cells may have originated from the patient or from another individual. The cells are most commonly derived from the immune system with the goal of improving immune functionality and characteristics. In autologous cancer immunotherapy, T cells are extracted from the patient, genetically modified and cultured in vitro and returned to the same patient. Comparatively, allogeneic therapies involve cells isolated and expanded from a donor separate from the patient receiving the cells.

<span class="mw-page-title-main">Cellectis</span> French biopharmaceutical company

Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.

<span class="mw-page-title-main">Nivolumab</span> Anticancer medication

Nivolumab, sold under the brand name Opdivo, is an anti-cancer medication used to treat a number of types of cancer. This includes melanoma, lung cancer, malignant pleural mesothelioma, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colon cancer, esophageal squamous cell carcinoma, liver cancer, gastric cancer, and esophageal or gastroesophageal junction cancer. It is administered intravenously.

Arie S. Belldegrun, FACS, is an Israeli-American urologic oncologist, billionaire businessman and investor.

The NK-92 cell line is an immortalised cell line that has the characteristics of a type of immune cell found in human blood called ’natural killer’ (NK) cells. Blood NK cells and NK-92 cells recognize and attack cancer cells as well as cells that have been infected with a virus, bacteria, or fungus. NK-92 cells were first isolated in 1992 in the laboratory of Hans Klingemann at the British Columbia Cancer Agency in Vancouver, Canada, from a patient who had a rare NK cell non-Hodgkin-lymphoma. These cells were subsequently developed into a continuously growing cell line. NK-92 cells are distinguished by their suitability for expansion to large numbers, ability to consistently kill cancer cells and testing in clinical trials. When NK-92 cells recognize a cancerous or infected cell, they secrete perforin that opens holes into the diseased cells and releases granzymes that kill the target cells. NK-92 cells are also capable of producing cytokines such as tumor necrosis factor alpha (TNF-a) and interferon gamma (IFN-y), which stimulates proliferation and activation of other immune cells.

Two River Group Holdings is a New York-based venture capital firm and merchant bank focused on the life science sector. It specializes in investments in life science, biotechnology, and in firms focused on developing preventive and therapeutic technologies for a broad spectrum of disease areas including oncology, cardiovascular disease, neurological disorders, and companion animal health care.

Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington, is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.

<span class="mw-page-title-main">Juno Therapeutics</span> American biopharmaceutical company

Juno Therapeutics Inc was an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. The company raised $300 million through private funding and a further $265 million through their IPO.

David G. Maloney is an oncologist and researcher at Fred Hutchinson Cancer Research Center and the University of Washington who specializes in developing targeted immunotherapies for the treatment of blood cancers.

Axicabtagene ciloleucel, sold under the brand name Yescarta, is a medication used for the treatment for large B-cell lymphoma that has failed conventional treatment. T cells are removed from a person with lymphoma and genetically engineered to produce a specific T-cell receptor. The resulting chimeric antigen receptor T cells (CAR-Ts) that react to the cancer are then given back to the person to populate the bone marrow. Axicabtagene treatment carries a risk for cytokine release syndrome (CRS) and neurological toxicities.

Lisocabtagene maraleucel, sold under the brand name Breyanzi, is a cell-based gene therapy used to treat B-cell lymphoma and follicular lymphoma.

The Immune Response Corporation (IRC) was a pharmaceutical company that worked in the development immunotherapeutic products. The firm was founded by Jonas Salk and Kevin Kimberlin when Kimberlin, "asked Salk to become lead scientific advisor for a new biotech company specializing in 'anti-idiotypes,' a novel vaccine technology." Salk called the proposal "liberating."

Brexucabtagene autoleucel, sold under the brand name Tecartus, is a cell-based gene therapy medication for the treatment of mantle cell lymphoma (MCL) and acute lymphoblastic leukemia (ALL).

T cell receptor T cell therapy (TCR-T) is a type of cancer immunotherapy. TCR-T therapies use heterodimers made of alpha and beta peptide chains to recognize MHC-presented polypeptide fragments molecules. Unlike CAR-T's cell surface antigens, TCR-T can recognize that larger set of intracellular antigen fragments. However, TCR-T cell therapy depends on MHC molecules, limiting its usefulness.

<span class="mw-page-title-main">Cellular adoptive immunotherapy</span> Cellular adoptive immunotherapy

Cellular adoptive immunotherapy is a type of immunotherapy. Immune cells such as T-cells are usually isolated from patients for expansion or engineering purposes and reinfused back into patients to fight diseases using their own immune system. A major application of cellular adoptive therapy is cancer treatment, as the immune system plays a vital role in the development and growth of cancer. The primary types of cellular adoptive immunotherapies are T cell therapies. Other therapies include CAR-T therapy, CAR-NK therapy, macrophage-based immunotherapy and dendritic cell therapy.

References

  1. 1 2 "Kite Pharma LEADERSHIP". March 10, 2023. Archived from the original on March 10, 2023. Retrieved March 10, 2023.
  2. 1 2 "Management Team". Kite Pharma. Archived from the original on July 17, 2017. Retrieved June 2, 2016.[ self-published source ]
  3. 1 2 3 4 5 6 Wright, Rob (January 31, 2020). "Allogene Therapeutics—The Juggernaut Built On Kite's Flight". Life Science Leader (Online). Pennsylvania: VertMarkets. ISSN   2161-0800 . Retrieved February 15, 2020.
  4. ↑ Puzzanghera, Jim (August 28, 2017). "Gilead is buying Kite Pharma, a cancer-fighting Santa Monica biotech firm, for $11.9 billion". Los Angeles Times . Archived from the original on June 25, 2022. Retrieved July 13, 2022.
  5. ↑ Grover, Natalie; Erman, Michael (August 28, 2017). "Gilead to buy Kite for promising cancer therapies in $12 billion deal". Reuters. Archived from the original on September 2, 2017. Retrieved December 19, 2019.
  6. ↑ Palmer, Eric (August 28, 2017). "Growth-hungry Gilead finally pivots from flagging hep C with $12B Kite buy". Fierce Pharma. Framingham, Massachusetts: Questex. Archived from the original on May 15, 2020. Retrieved December 19, 2019.
  7. ↑ "Gilead Sciences Completes Acquisition of Kite Pharma, Inc" (Press release). Gilead Sciences. October 3, 2017. Retrieved December 19, 2019.[ self-published source ]
  8. ↑ "Kite's Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy" (Press release). Gilead Sciences. 18 October 2017. Retrieved 19 Dec 2019.[ self-published source ]
  9. ↑ Richtel, Matt; Pollack, Andrew (December 19, 2016). "Harnessing the U.S. Taxpayer to Fight Cancer and Make Profits" . The New York Times . ISSN   0362-4331. Archived from the original on June 27, 2022. Retrieved July 13, 2022.
  10. ↑ "What are the 50 Smartest Companies?". MIT Technology Review . June 27, 2017. 7 Kite Pharma. Archived from the original on November 12, 2017. Retrieved December 19, 2019.
  11. 1 2 "Kite Pharma (KITE) Announces Initiation of KTE-C19 Phase 1/2". StreetInsider.com. December 2, 2015. Archived from the original on December 20, 2019. Retrieved December 19, 2019.
  12. 1 2 "Kite Pharma (KITE) Announces KTE-C19 for NHL Granted FDA Breakthrough Therapy Designation". StreetInsider.com. December 7, 2015. Archived from the original on December 20, 2019. Retrieved December 19, 2019.
  13. ↑ "Kite Pharma Partners with the National Cancer Institute to Develop Novel Cellular Immunotherapy Clinical Products" (Press release). Kite Pharma. October 16, 2012. Archived from the original on August 9, 2014. Retrieved August 15, 2014.[ self-published source ]
  14. ↑ "Kite Pharma's Lead Program with the National Cancer Institute (NCI) Demonstrates Positive Results in Patients with Aggressive Non-Hodgkin's Lymphoma" (Press release). Kite Pharma. December 7, 2013. Archived from the original on August 9, 2014. Retrieved August 15, 2014.[ self-published source ]
  15. ↑ "Donor-derived allogeneic T cells may cause regression of B-cell malignancies". Meeting News Coverage. Healio. Thorofare, New Jersey: SLACK Incorporated. December 7, 2013. Archived from the original on March 7, 2016. Retrieved December 19, 2019.
  16. ↑ "Kite Pharma Announces FDA Orphan Drug Designation for Anti-CD19 T Cell Cancer Immunotherapy Product" (Press release). Kite Pharma. March 31, 2014. Archived from the original on January 12, 2015. Retrieved May 19, 2014.[ self-published source ]
  17. ↑ "Kite Pharma Announces Exclusive License with The National Institutes of Health for T Cell Receptor (TCR)-Based Products Targeting NY-ESO-1 For Multiple Cancer Indications" (Press release). Kite Pharma. June 6, 2014. Archived from the original on August 11, 2014. Retrieved June 8, 2014.[ self-published source ]
  18. ↑ Ro, Sam (August 26, 2014). "Biotech Stock Kite Pharma Explodes Higher After Good News About Its Non-Hodgkin Lymphoma Drug" Archived 2014-08-27 at the Wayback Machine . Business Insider . Retrieved August 27, 2014.
  19. ↑ "Amgen, Kite Pharma ink deal to develop cancer immunotherapies". Reuters. January 5, 2015. Archived from the original on December 8, 2015. Retrieved January 21, 2015.
  20. ↑ "Amgen and Kite Pharma Announce Strategic Cancer Immunotherapy Collaboration to Advance the Application of Novel Chimeric Antigen Receptor (CAR) T Cell Therapies" (Press release). Kite Pharma. January 5, 2015. Archived from the original on January 21, 2015.
  21. ↑ "Kite Pharma Announces That the First Patient in Its Phase 1/2 Clinical Trial Has Been Treated With KTE-C19, Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, for Refractory Aggressive Non-Hodgkin's Lymphoma (NHL) " Archived 2015-07-08 at the Wayback Machine . MarketWatch. 21 May 2015. Retrieved 7 July 2015.
  22. ↑ "Kite Pharma & Bluebird Bio To Co-develop T Cell Cell Therapy Products" Archived 2015-07-08 at the Wayback Machine . NASDAQ. 22 June 2015. Retrieved 7 July 2015.
  23. ↑ "Kite Pharma (KITE), Leukemia & Lymphoma Society Enter Into Collaboration" Archived 2015-07-08 at the Wayback Machine . StreetInsider.com. 1 July 2015. Retrieved 7 July 2015.
  24. ↑ "Kite Pharma Expands Collaboration With Netherlands Cancer Institute (NKI)" Archived 2015-12-08 at the Wayback Machine . Kite Pharma. 14 September 2015. Retrieved 20 October 2015.
  25. ↑ "Kite Pharma Announces Exclusive License with the National Institutes of Health for T Cell Receptor (TCR)-Based Products to Treat Tumors Expressing MAGE" Archived 2015-10-23 at the Wayback Machine . FiereceBiotech. 20 October 2015. Retrieved 20 October 2015.
  26. ↑ "Kite to spend as much as $530 million on rights to AIS programs " Archived 2015-12-08 at the Wayback Machine . ThePharmaLetter. 28 October 2015. Retrieved 28 October 2015.
  27. ↑ Demmitt, Jacob (28 October 2015). "Seattle’s Alpine Immune Sciences licenses cancer treatment to Kite Pharma for up to $530M" Archived 2015-10-28 at the Wayback Machine . GeekWire. Retrieved 28 October 2015.
  28. ↑ "Kite Pharma, GE Global Research Partner on T-Cell Therapy Manufacturing" Archived 2015-12-07 at the Wayback Machine . Genetic Engineering & Biotechnology News. 3 December 2015. Retrieved 7 December 2015.
  29. ↑ "Kite Pharma (KITE), NCI Expand Clinical and Research Partnership" Archived 2016-03-04 at the Wayback Machine . TheStreet.com. 7 January 2015. Retrieved 7 January 2015.
  30. ↑ "Kite Pharma and Leiden University Medical Center Sign Research and License Agreement for T Cell Receptors Targeting HPV-Associated Cancers" Archived 2016-01-15 at the Wayback Machine . FierceBiotech. 13 January 2016. Retrieved 13 January 2016.
  31. ↑ Sandford, Miles (18 March 2016). "Kite Pharma Inc (NASDAQ:KITE) To Begin a Collaborative Study on KTE-C19" Archived 2016-03-18 at the Wayback Machine . Journal Transcript. Retrieved 18 March 2016.
  32. ↑ "Kite Pharma (KITE), Cell Design Labs Enter Research Collaboration for Next-Gen CAR Product Candidates" Archived 2016-06-03 at the Wayback Machine . StreetInsider.com. 2 June 2016. Retrieved 2 June 2016.
  33. ↑ "Kite Pharma Expands Development of T-Cell Receptor (TCR) Therapies Targeting HPV-Associated Cancers in Partnership with the National Cancer Institute (NCI)" Archived 2016-06-21 at the Wayback Machine . BusinessWire. 20 June 2016. Retrieved 20 June 2016.
  34. ↑ "Kite Pharma Licenses Enabling Technology for the Development of Off-the-Shelf Allogeneic T-Cell Therapies " Archived 2016-07-26 at the Wayback Machine . BusinessWire. 25 July 2016. Retrieved 26 July 2016.
  35. ↑ "Kite Pharma (KITE) Enters Strategic Partnership with Vitruvian Networks" Archived 2016-12-20 at the Wayback Machine . StreetInsider.com. 13 December 2016. Retrieved 14 December 2016.
  36. ↑ Whipple, Tom (2017-03-01). "New gene therapy 'shrinks tumours like ice cubes'" . The Times. Archived from the original on 2017-03-01. Retrieved 2017-03-01.
  37. ↑ "Kite Wins ‘Clinical Trial Result of the Year’ for its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 Clinical and Research Excellence Awards" Archived 2017-04-07 at the Wayback Machine . Yahoo Finance. 6 April 2017. Retrieved 7 April 2017.
  38. ↑ Taylor, Phil (1 August 2017). "Kite files first CAR-T candidate in Europe" Archived 2017-08-09 at the Wayback Machine . PMLive. Retrieved 9 August 2017.
  39. ↑ “Kite Pharma Raises $15 Million in Initial Round of Financing and Appoints David Bonderman to Board of Directors” Archived 2014-08-11 at the Wayback Machine . Kite Pharma . 9 March 2011. Retrieved 29 July 2014.
  40. ↑ “Kite Pharma Completes $35 Million Series A Preferred Stock Financing” Archived 2014-08-09 at the Wayback Machine . Kite Pharma . 15 May 2013. Retrieved 15 August 2014.
  41. ↑ Orbach, Meir (18 May 2014). "טיפול לסרטן שפותח ברחובות נמצא בדרך לנאסד"ק" Archived 2014-05-19 at the Wayback Machine (In Hebrew). Calcalist (Tel Aviv). Retrieved 19 May 2014.
  42. ↑ McBride, Ryan (15 May 2013). "UPDATED: Billionaires back Kite Pharma in $20M raise for cancer immunotherapies" Archived 2014-05-19 at the Wayback Machine . FierceBiotech. Retrieved 19 May 2014.
  43. ↑ " Kite Pharma, Inc. Completes $50 Million Mezzanine Private Financing" Archived 2014-08-11 at the Wayback Machine . Kite Pharma. 28 April 2014. Retrieved 19 May 2014.
  44. ↑ Carroll, John (28 April 2014). "Immuno-oncology specialist Kite adds $50M in new financing" Archived 2014-05-19 at the Wayback Machine . FierceBiotech. Retrieved 19 May 2014.
  45. ↑ “Kite Pharma Files Registration Statement for Proposed Initial Public Offering” Archived 2014-08-09 at the Wayback Machine . Kite Pharma. 19 May 2014. Retrieved 19 May 2014.
  46. ↑ “Kite Pharma Announces Pricing of Initial Public Offering” Archived 2014-08-11 at the Wayback Machine . Kite Pharma. 20 June 2014. Retrieved 15 August 2014.
  47. ↑ Calia, Michael (20 June 2014). "Kite Pharma Soars Above IPO Price on First Day of Trading" Archived 2014-06-22 at the Wayback Machine . The Wall Street Journal. Retrieved 21 June 2014.
  48. ↑ “Kite Pharma Announces Full Exercise of Underwriters' Option to Purchase Additional Shares” Archived 2014-07-17 at the Wayback Machine . Kite Pharma. 23 June 2014. Retrieved 15 August 2014.
  49. ↑ "Kite Pharma Announces Pricing of Follow-On Offering". Reuters. 10 December 2014. Retrieved 10 December 2015.
  50. ↑ "Kite Pharma Acquires T-Cell Factory for $21M Up Front" Archived 2015-03-23 at the Wayback Machine . Genetic Engineering & Biotechnology News . 18 March 2015. Retrieved 18 March 2015.
  51. ↑ Zacks.com (18 March 2015)."Kite Pharma (KITE) Acquires T-Cell Factory, Focus on Europe - Analyst Blog" Archived 2015-03-20 at the Wayback Machine . NASDAQ . Retrieved 18 March 2015.
  52. ↑ "Kite Pharma Announces Pricing of Public Offering of Common Stock" Archived 2015-12-22 at the Wayback Machine . Reuters. 10 December 2015. Retrieved 10 December 2015.
  53. ↑ Grover, Divya (9 January 2017). "Kite Pharma partners with Japan's Daiichi for cancer therapy" Archived 2017-01-12 at the Wayback Machine . Reuters. Retrieved 10 January 2017.
  54. ↑ Mukhopadhyay, Akankshita (10 January 2017). "Kite, Fosun Pharma form JV in China for cancer treatment" Archived 2017-01-11 at the Wayback Machine . Reuters. Retrieved 10 January 2017.
  55. ↑ "Gilead | Investors | News Release". investors.gilead.com (Press release). Retrieved 2017-08-28.[ self-published source ][ permanent dead link ]
  56. ↑ "Gilead Sciences Completes Acquisition of Kite Pharma, Inc". Newsroom (Press release). Gilead. October 3, 2017. Retrieved 15 Feb 2020.[ self-published source ]
  57. ↑ Gartner, Emmett (10 January 2023). "Kite announces Urbana facility expansion, 100 new jobs" . Frederick News-Post . Archived from the original on 11 January 2023. Retrieved 10 January 2023.
  58. ↑ "Kite Completes Acquisition of Tmunity". Archived from the original on 2023-02-27. Retrieved 2023-02-27.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.